gastroenterology
IBD

Combo IBD therapy loses edge in long-term

Anti-TNF monotherapy is not inferior to combination therapy in terms of remission and loss of response rates over the long-term in people with IBD. According to a retrospective audit of 224 patients receiving anti-TNF therapy for IBD in Melbourne, 45% of patients had a loss of response during 8.5 years of follow-up. Patients were mostly ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic